(CTMX) - Analyzing CytomX Therapeutics's Short Interest
Portfolio Pulse from Benzinga Insights
CytomX Therapeutics (NYSE:CTMX) has seen a significant rise in its short interest, with a 143.23% increase since the last report. The company now has 8.75 million shares sold short, representing 11.31% of its float. This is higher than the peer group average of 6.21%. The increase in short interest could indicate bearish sentiment among investors.
June 05, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
CytomX Therapeutics has experienced a 143.23% increase in short interest, now at 11.31% of its float. This could indicate bearish sentiment among investors.
The significant increase in short interest suggests that more investors are betting against the stock, which could lead to downward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100